[go: up one dir, main page]

AR119865A1 - Proteínas de unión a cr2 y su uso en tratamientos médicos - Google Patents

Proteínas de unión a cr2 y su uso en tratamientos médicos

Info

Publication number
AR119865A1
AR119865A1 ARP200102433A ARP200102433A AR119865A1 AR 119865 A1 AR119865 A1 AR 119865A1 AR P200102433 A ARP200102433 A AR P200102433A AR P200102433 A ARP200102433 A AR P200102433A AR 119865 A1 AR119865 A1 AR 119865A1
Authority
AR
Argentina
Prior art keywords
binding proteins
medical treatments
ebv
barr
epstein
Prior art date
Application number
ARP200102433A
Other languages
English (en)
Inventor
James Matthew Bailey
Gerben Bouma
Michael Neil Burden
Caroline J Dimech
David Dixon
Santos Cruz De Mantos Gabriela Dos
Christian Ellson
Laura J Hook
Semra Kitchen
Eleanora Lekova
Emilie Madura
Kiran Nistala
Jian Zhang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR119865A1 publication Critical patent/AR119865A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente proporciona proteínas de unión a CR2 que se unen al CR2 humano, composiciones farmacéuticas que comprenden dichas proteínas de unión a CR2 y su uso en el tratamiento o la prevención de afecciones autoinmunes y/o inflamatorias, enfermedades infecciosas y neoplasias asociadas al virus de Epstein-Barr (EBV); y su uso como adyuvantes de vacunas / vehículos de antígenos.
ARP200102433A 2019-08-30 2020-08-28 Proteínas de unión a cr2 y su uso en tratamientos médicos AR119865A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1912437.9A GB201912437D0 (en) 2019-08-30 2019-08-30 CR2 Binding Proteins and their use in Medical Therapy

Publications (1)

Publication Number Publication Date
AR119865A1 true AR119865A1 (es) 2022-01-19

Family

ID=68207176

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102433A AR119865A1 (es) 2019-08-30 2020-08-28 Proteínas de unión a cr2 y su uso en tratamientos médicos

Country Status (14)

Country Link
US (1) US20230032643A1 (es)
EP (1) EP4021938A1 (es)
JP (1) JP7603061B2 (es)
KR (1) KR20220053000A (es)
CN (1) CN114375305A (es)
AR (1) AR119865A1 (es)
AU (1) AU2020338807A1 (es)
BR (1) BR112022003623A2 (es)
CA (1) CA3151687A1 (es)
GB (1) GB201912437D0 (es)
IL (1) IL290649A (es)
MX (1) MX2022002478A (es)
TW (1) TWI851801B (es)
WO (1) WO2021038023A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
EP1001021B1 (en) * 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
CN1511041A (zh) * 2001-05-17 2004-07-07 ������ҩ�����޹�˾ 利用抑制cd21的药剂治疗抗体介导的病变的方法
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
HRP20161542T1 (hr) 2009-11-30 2016-12-30 Janssen Biotech, Inc. MUTIRANA Fc ANTITIJELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM
SG185483A1 (en) * 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
CN108137669B (zh) * 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
US11214603B2 (en) * 2016-04-27 2022-01-04 The Regents Of The University Of Michigan C3D cellular and acellular vaccines for the prevention and treatment of cancer

Also Published As

Publication number Publication date
AU2020338807A8 (en) 2022-06-02
TW202126687A (zh) 2021-07-16
JP2022545947A (ja) 2022-11-01
WO2021038023A1 (en) 2021-03-04
AU2020338807A1 (en) 2022-03-10
EP4021938A1 (en) 2022-07-06
CA3151687A1 (en) 2021-03-04
JP7603061B2 (ja) 2024-12-19
BR112022003623A2 (pt) 2022-05-24
MX2022002478A (es) 2022-03-22
TWI851801B (zh) 2024-08-11
IL290649A (en) 2022-04-01
CN114375305A (zh) 2022-04-19
US20230032643A1 (en) 2023-02-02
KR20220053000A (ko) 2022-04-28
GB201912437D0 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
CL2021000088A1 (es) Anticuerpos anti-cd27 (divisional de solicitud 779-2019).
MX2018009917A (es) Vacuna contra el virus del zika.
CL2019000643A1 (es) Anticuerpos de unión a cd3.
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
ECSP099547A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA201691443A1 (ru) Накожное восстановление иммунобаланса
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
AR101814A1 (es) Partícula de tipo virus flavivirus
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EA201590111A1 (ru) Моноклональное антитело человека против белка vp1 вируса jc
NZ594198A (en) Neil3 peptides and vaccines including the same
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
EA201491969A1 (ru) Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
EA201891555A1 (ru) Вирус вакцины от репродуктивно-респираторного синдрома свиней
AR119865A1 (es) Proteínas de unión a cr2 y su uso en tratamientos médicos
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
MX2022001430A (es) Formulaciones de vacuna contra chikungu?a.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal